Free Trial
NASDAQ:AGEN

Agenus (AGEN) Stock Price, News & Analysis

$15.25
+1.63 (+11.97%)
(As of 05/28/2024 ET)
Today's Range
$13.85
$16.15
50-Day Range
$4.97
$15.25
52-Week Range
$4.78
$42.60
Volume
1.07 million shs
Average Volume
686,001 shs
Market Capitalization
$320.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00

Agenus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
359.0% Upside
$70.00 Price Target
Short Interest
Bearish
15.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.51mentions of Agenus in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.70) to ($8.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

251st out of 931 stocks

Biological Products, Except Diagnostic Industry

35th out of 154 stocks

AGEN stock logo

About Agenus Stock (NASDAQ:AGEN)

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Stock Price History

AGEN Stock News Headlines

7 Biotech Stocks to Put on Your Breakthrough Radar
Agenus (NASDAQ:AGEN) Stock Rating Reaffirmed by HC Wainwright
Agenus sets FDA meeting for cancer therapy path
Agenus: Q1 Earnings Snapshot
Agenus Reports First Quarter 2024 Results
Time Is Running Out For Agenus To Raise Cash
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/28/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.00
High Stock Price Target
$100.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+359.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-245,760,000.00
Net Margins
-154.88%
Pretax Margin
-154.88%

Debt

Sales & Book Value

Annual Sales
$156.31 million
Book Value
($7.78) per share

Miscellaneous

Free Float
20,033,000
Market Cap
$320.25 million
Optionable
Optionable
Beta
1.25
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Founder, Executive Chairman & CEO
    Comp: $1.34M
  • Ms. Christine M. Klaskin (Age 58)
    VP of Finance, Principal Financial Officer & Principal Accounting Officer
    Comp: $407.44k
  • Dr. Steven J. O'Day M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $970.98k
  • Craig Winter
    Chief Information Officer
  • Mr. Zack Armen
    Head of Investor Relations
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • Mr. Alfred Dadson
    Chief Manufacturing Officer
  • Mr. Eric Humes
    Chief Quality Officer
  • Dr. Todd Jude Yancey M.D.
    Member of Advisory Board & Chief Strategic Advisor
  • Dr. Robin G. Taylor M.B.A.
    Ph.D., Chief Commercial Officer

AGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price targets for Agenus' stock. Their AGEN share price targets range from $40.00 to $100.00. On average, they anticipate the company's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 359.0% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2024?

Agenus' stock was trading at $16.5580 at the beginning of 2024. Since then, AGEN stock has decreased by 7.9% and is now trading at $15.25.
View the best growth stocks for 2024 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings results on Tuesday, May, 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.54. The biotechnology company earned $28.01 million during the quarter, compared to the consensus estimate of $40.70 million.

What ETFs hold Agenus' stock?

ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

When did Agenus' stock split?

Agenus's stock reverse split on the morning of Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
Who are Agenus' major shareholders?

Agenus' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (169.59%), GSA Capital Partners LLP (6.27%), Oracle Investment Management Inc. (5.08%), Key Client Fiduciary Advisors LLC (4.10%), Acadian Asset Management LLC (3.73%) and Hennion & Walsh Asset Management Inc. (2.67%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGEN) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners